SynthesisFrontiers in pharmacology2026
Preclinical evaluation of puerarin for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kudzu root is commonly prescribed in traditional Chinese medicine for non-alcoholic fatty liver disease (NAFLD). Its key active ingredient, puerarin, has shown promising protective effects in experimental NAFLD models. Yet the overall efficacy and the main biological mechanisms have not been systematically assessed. Objective: This meta-analysis will synthesize evidence from animal studies to determine how puerarin influences liver-related outcomes in NAFLD. It will also summarize the mechanistic pathways that may account for these effects. Method: Literature retrieval was performed up to September 2025, encompassing eight databases. The risk of bias in the included studies was evaluated using the SYRCLE assessment tool. Data analyses were then performed in Stata 15. The primary outcome included triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Secondary outcome comprised interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), superoxide dismutase (SOD), malondialdehyde (MDA), and glutathione peroxidase (GSH-Px). Subgroup analyses, publication bias assessments, and sensitivity analyses were performed to ensure the robustness. Results: 20 studies were included, involving 331 animals. Puerarin treatment significantly reduced levels of TG, TC, and LDL-C, while improving HDL-C in animal models of NAFLD. Additionally, puerarin significantly upregulated antioxidant indicators SOD and GSH-Px and lowered MDA levels. Furthermore, it inhibited the expression of inflammatory factors IL-6, IL-1β, and TNF-α. Conclusion: This meta-analysis concludes that puerarin demonstrates substantial liver-protective effects in NAFLD models by regulating lipid metabolism, anti-inflammatory, and antioxidant. Collectively, these finding lays a solid evidence-based foundation for the subsequent advancement of clinical translation research and the in-depth exploration of its underlying mechanisms. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, Identifier CRD420251170089.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.